Search
Menu
Home
HTB
2005
January
29
HTB
29 January 2005
Contents
Conference reports
Paradoxical CD4 response with tenofovir and ddI backbone
Tenofovir/FTC backbone outperforms AZT/3TC (Combivir) with efavirenz in treatment naive patients; reduced toxicity drives ITT viral efficacy
Limited stability of lopinavir/r (Kaletra) above 25°C
Atorvastatin requires dose reduction with tipranavir/r
Once-daily T-20 is less effective than twice daily: lower potency is related to C trough
Further genetic link to efavirenz absorption
Long-term response to FTC in children is similar to adults
Side effects update: hypersensitivity, heart, bones
Antiretrovirals
Roche discontinue plans for nelfinavir 625mg formulation
Treatment access
Generic ARVs and WHO prequalification list
Cotrimoxazole reduces mortality and morbidity in HIV-positive children: joint WHO/UNAIDS/UNICEF statement
Equitable access for antiretroviral treatment for women
Guidelines
US treatment guidelines updated (Jan 2005)
Updated UK guidelines for HIV and hepatitis coinfection (2005)
Hepatitis coinfection
Interferon plus 3TC for people with HIV/HBV coinfection
On the web
55th Annual Meeting of the American Society for the Study of Liver Diseases (55th AASLD), 29 October – 2 November, 2004, Boston MA
Conference abstracts and reports
Update your WHO/EDM bookshelf
HIV InSite Knowledge Base
Journal articles online at Medscape
Facing up to it: Bio-Alcamid as a facial filler to treat lipoatrophy
HTB RSS
Current issues
April 2024
March 2024
February 2024
Back issues
Special report
Uganda Court rejects appeal against the LGBTQ+ hate law
5 April 2024
More from HTB
Conference reports
Conference shortcuts
Articles by subject
PDFs
Subscribe
HTB homepage
Home
i-Base homepage